(30) Priority Data:
08/286,745 5 August 1994 (05.08.94) US
08/473,040 6 June 1995 (06.06.95) US

(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US/US); 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).

(72) Inventors: McGrath, Michael S.; 1452 Benito Avenue, Burlingame, CA 94010 (US). Herndier, Brian; 56 Van Buren, San Francisco, CA 94131 (US). Shiramizu, Bruce; 365 Carmel Avenue, Pacifica, CA 94044 (US).

(74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, 201 N. Figueroa Street, 5th Street, Los Angeles, CA 90012-2628 (US).

(54) Title: DIAGNOSIS AND TREATMENT OF CELL PROLIFERATIVE DISEASE HAVING CLONAL MACROPHAGE INVOLVEMENT

(57) Abstract

The presence of clonal macrophages in pre-cancerous and cancerous tissue represents an early stage of the disease in which clonal expansion of macrophages occurs due to HIV integration or other genetic mutation. Clonally expanded macrophages induce proliferation of surrounding tissue leading to cancerous tumor growth. The invention provides methods and kits for diagnosis of HIV- and non-HIV-associated clonal expansion of macrophages in pre-cancerous and cancerous tissue and other cell proliferative diseased tissue. The invention also provides methods for the treatment of cell proliferative diseases induced by clonal macrophage expansion and proliferation of surrounding tissue.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>Code</th>
<th>Name</th>
<th>Code</th>
<th>Name</th>
<th>Code</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MA</td>
<td>Mauritania</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GE</td>
<td>Georgia</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GN</td>
<td>Guinea</td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GR</td>
<td>Greece</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>HU</td>
<td>Hungary</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>IE</td>
<td>Ireland</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IT</td>
<td>Italy</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>JP</td>
<td>Japan</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>KR</td>
<td>Kenya</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SI</td>
<td>Slovenia</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LU</td>
<td>Luxembourg</td>
<td>SK</td>
<td>Slovakia</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>LV</td>
<td>Latvia</td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>CS</td>
<td>Czechoslovakia</td>
<td>MC</td>
<td>Monaco</td>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>MD</td>
<td>Republic of Moldova</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>MG</td>
<td>Madagascar</td>
<td>TJ</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>ML</td>
<td>Mali</td>
<td>TT</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
<td>MN</td>
<td>Mongolia</td>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
<td></td>
<td></td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
<td></td>
<td></td>
<td>UZ</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>GA</td>
<td>Gabon</td>
<td></td>
<td></td>
<td>VN</td>
<td>Viet Nam</td>
</tr>
</tbody>
</table>
DIAGNOSIS AND TREATMENT OF CELL PROLIFERATIVE DISEASE HAVING CLONAL MACROPHAGE INVOLVEMENT

Cross-Reference to Related Application

This application is a continuation-in-part of our earlier filed (pending) U.S. application Serial No. 08/286,745, filed August 5, 1994 which application is incorporated herein by reference in its entirety and to which application we claim priority under 35 USC §120.

Statement as to Federally Sponsored Research

This invention was made at least in part with funds from the Federal government, and the government therefore may have certain rights in the invention.

Field of the Invention

The field of the invention relates to therapy for cell proliferative diseases; human immunodeficiency virus; a recombinant macrophage; methods of diagnosis of macrophage involvement in cell proliferative disease; kits for use in diagnosis; and methods of treatment for cell proliferative disease involving macrophage-induced tissue growth.

Background of the Invention

Diseases caused by excessive, uncontrolled cell proliferation account for thousands of life threatening diseases diagnosed each year. Cell proliferative diseases include the various cancers as well as diseases whose etiology has only recently been correlated with cell proliferation. Particular examples include astrocyte proliferation in the brains of AIDS dementia patients, atherosclerosis, glomerulosclerosis resulting from retroviral-induced renal disease.

Lymphomas are a common form of cancer in HIV-infected patients. Of the approximately 36,000 new cases of lymphoma diagnosed in the United States in 1992,
between 8 and 27% are estimated to have occurred in HIV-infected individuals (Gail, M.H. et al., *J Natl Can Int* (1991) *83*:695-701). Thus, HIV-related lymphoma represents a major clinical problem for physicians involved in the care of HIV-infected individuals.


Lymphomas, in general, are a heterogeneous group of malignancies. Their biologic behavior ranges from indolent, requiring no therapy, to aggressive malignancies with few long-term survivors. The behavior of lymphoma is influenced by the immune status of the host. The risk of B-cell lymphoma is dramatically increased in individuals with defects of cell-mediated immunity. The best characterized of these groups is immunosuppressed allograft recipients, whose risk of developing lymphoma is between 50 and 60 times that of the general population. These individuals develop a

The primary means of HIV lymphoma diagnosis remains microscopic examination of hematoxylin and eosin-stained sections from formalin-fixed tissue. Over time, pathologists have used clinical presentations, autopsy follow-up, and trial and error to develop histologic methods of diagnosing and categorizing cancer. Missing a histologic diagnosis of cancer or 'over-calling' a cancer and subjecting a patient to cancer therapy are sufficient incentives for providing accurate diagnosis. Traditional histologic methods can be enhanced by phenotypic and, particularly, genotypic analyses of lymphomas where the discerned molecular changes of the affected tissue point to an alternative form of treatment.

Summary of the Invention

The invention relates to methods of diagnosing clonal macrophage involvement in cell proliferative disease using genotypic analysis. The method of the invention is applicable to a variety of cell proliferative diseases including, but not limited to, HIV-associated and non-HIV-associated lymphomas or other cancers as well as non-cancerous cell proliferative
disease such as AIDS dementia, atherosclerosis, and nephropathy. The invention also relates to kits for such diagnostic methods, methods of treating macrophage-induced cell proliferative diseases, and a recombinant macrophage useful in vitro and in vivo methods of screening for therapeutic agents useful in treating macrophage-induced cancer.

The discovery that HIV lymphomas are frequently associated with clonal macrophage involvement and that the macrophage has HIV DNA integrated upstream of a known oncogene, c-fes (c-fes/fps), is disclosed. As described in detail below, macrophage clonality is associated with many HIV-related lymphomas. Macrophage clonality can be associated with non-HIV-related lymphomas as well.

Expansion of macrophages may enhance growth of surrounding tissue by secretion of cytokines; the cytokine Interleukin-6 has been shown to cause growth of myeloma and hybridoma cells (Woodruff, C. et al., DNA and Cell Biology 11:587-592).

Diagnosis of macrophage clonality and treatment which targets clonal macrophages offers a new direction in cell proliferative disease therapy. Disclosed are diagnostic methods and kits as well as therapeutic methods useful in the battle to overcome clonal macrophage-induced HIV lymphomas and clonal macrophage-induced cell proliferative diseases in general.

Accordingly, in one aspect, the invention features a method of diagnosing the presence of clonally expanded macrophages in a diseased tissue of a mammal by first obtaining a sample of the tissue suspected of having a cell proliferative lesion followed by isolation of DNA from the tissue by standard techniques known to those of ordinary skill in the art of molecular biology. The presence of clonal DNA in the isolated DNA is determined by standard techniques including, but not limited to, HIV integration site analysis by IPCR (Shiramizu, B. et al., Cancer Res (1994) 54:2069-2072); RFLP (Restriction
Fragment Length Polymorphism) analysis of genomic sequences near common sites of viral (e.g., HIV) integration; or immunoglobulin (Ig) gene rearrangement analysis (Levy, R. et al., J Exp Med (1977) 145:1014-1028). Preferentially, this analysis includes mixing known quantities of control monoclonal DNA and control polyclonal DNA such that, following Southern analysis, the DNA band intensity of a 5% monoclonal mixture is determined and used as a standard against which the clonality of the test DNA is compared. Using this technique, monoclonal macrophages are those defined as having more than a 5% monoclonal DNA component within analyzed tissue. Preferably, the technique of inverse polymerase chain reaction (IPCR) used to determine the clonality of a tissue sample containing integrated HIV is a valuable diagnostic tool and is defined in detail below.

The invention also features a kit for the diagnosis of macrophage-induced pre-cancerous and cancerous tissue as tissue containing greater than 5% monoclonal DNA from macrophages. The kit of the invention features nucleic acid primers for amplifying DNA of an HIV-containing cell (e.g., a macrophage). The nucleic acid primers for amplification of HIV-containing DNA preferentially hybridize to regions of the 5' and /or 3' long terminal repeats (LTRs) such that DNA synthesis is primed in opposite directions for IPCR analysis. The kit also includes a labeled (e.g., radiolabeled; biotinylated; or other standard label) or detectable probe for the RFLP analysis of genomic DNA for clonality where priming of HIV sequences is not desirable (e.g., in non-HIV-related cancers). Such a probe hybridizes to a genetic locus in which genetic alteration is associated with cellular proliferation (such as a common site of viral integration leading to cellular proliferation). Such sites include a site into which a virus can integrate and drive a growth promoting cell proliferation gene. A kit of the
invention can also include antibodies for detecting macrophage-specific cell surface proteins to isolate and identify macrophages in a tissue sample.

The diagnostic method of the invention features comparing the clonality of test DNA to control HIV-containing DNA to indicate involvement of HIV-containing clonal cells (e.g., clonal macrophage) in the tissue morphology. The involvement of clonal macrophages is determined by initial sorting into cellular subpopulations (by fluorescence activated cell sorting (FACS) technique or macrophage adherence to glass or plastic; or other technique well known in the art) followed by DNA analysis. Alternatively, analysis of DNA from a mixed cellular population is performed followed by dual staining or in situ hybridization of a tissue preparation to correlate clonal HIV with the macrophages.

The diagnostic method of the invention also features analysis of the clonality of non-HIV-associated macrophages. The method involves isolating test DNA from a mixture of cells or a pre-sorted subpopulation of macrophages from pre-cancerous or cancerous tissue followed by RFLP analysis of the test DNA. RFLP analysis of the invention utilizes a nucleic acid probe that hybridizes to a genomic sequence encoding a common viral (e.g., HIV) integration site associated with cellular proliferation upon viral integration. For example, HIV integration into genomic DNA in the z exon of the fur gene has been observed in both T-cells (Shiramizu, B., et al. (1994), supra) and in macrophages as described herein.

Using the diagnostic method of the invention, the absence of HIV clonality can indicate a non-HIV-associated clonal macrophage involvement in the tissue morphology. The absence of both HIV and macrophage involvement is also discernable using the kit of the invention. The diagnosis of macrophage involvement provides the clinician with powerful information for
designing an appropriate treatment regimen for the patient.

The invention features a macrophage having integrated in its genome a transcriptional/translational controlling sequence operably attached to a cell proliferation gene such that expression of the cell proliferation gene results in (expansion) of the macrophage. Cell proliferation can be the result of substantially increased expression of a cytokine gene or other cell proliferation gene such as an oncogene. For example, integration into the z exon of the macrophage fur gene of a strong promoter and/or enhancer element (e.g., an HIV genome; a defective HIV genome wherein the enhancer region of an HIV 3' LTR is functional; the enhancer region of an HIV 3' LTR; or other promoter or enhancer element capable of substantially increasing expression of a nearby gene (whereby nearby is meant within about 12 kb, preferably about 10 kb, or more preferably about 5 kb of the transcriptional start site) such that expression of the downstream c-fes/fps gene is substantially increased relative to c-fes/fps expression in a macrophage having no promoter or enhancer element integrated within it. HIV integration in or near the c-sis (PDGF-B gene) of a macrophage promotes macrophage proliferation.

Integration of a DNA sequence encoding a strong promoter and (optionally an enhancer element) operably attached to a growth promoting cell proliferation gene into the macrophage genome is accomplished by standard molecular biology techniques (e.g., delivery of the transfecting DNA in liposomes) (see e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Green Publishing Associates, Cold Spring Harbor Laboratory Press, 1989; and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, new York, 1989). Recombinant macrophages are screened for increased c-fes/fps expression by techniques described herein.
Alternatively, the transcriptional/translational controlling regions are fused to a cell proliferation gene on a DNA expression cassette which is integrated into the macrophage genome. Expression of the cell proliferation gene of the cassette also results in cell proliferation. Recombinant macrophages are also screened for the ability to enhance cell proliferation relative to non-recombinant macrophages when introduced into a population of B- and/or T-cells.

Macrophages which express increased levels of cell proliferation controlling gene such as the oncogene c-fes/fps or c-sis are useful for screening therapeutic agents in vitro for the ability to inhibit growth of such macrophages. The screening method of the invention provides cultured recombinant macrophages expressing a substantially increased level of c-fes/fps or c-sis in an appropriate culture medium. To the cultured recombinant macrophages is added a therapeutic agent in an appropriate formulation for delivery of the therapeutic agent to the recombinant macrophage. The effect of administration of the agent is monitored as reduced cell growth, reduced cell viability, reduced c-fes/fps or c-sis expression, and/or reduced cytokine expression. Methods of monitoring cell growth and viability are well known in the art. Methods of monitoring c-fes/fps and cytokine expression are described herein. Therapeutic agents which cause reduction in the monitored phenotypes are selected as candidate compounds or formulations for treatment of macrophage-induced cancers such as those listed in Table II.

The invention features a method of screening candidate therapeutic agents in vivo for the ability to substantially eliminate a recombinant macrophage (e.g., a clonally expanded macrophage having a transcription controlling sequence integrated for the increased expression of a cell proliferation gene) from the host. The recombinant macrophage is injected into the
appropriate tissue of the host (e.g., the spleen, the peripheral blood, the skin, or the bone marrow) and growth of a tumor containing the recombinant macrophage is monitored. To the host is then administered a candidate therapeutic agent in a formulation for preferential uptake by a macrophage, wherein the administering is performed at a dose, an interval, and for a duration that is sufficient to substantially eliminate the recombinant macrophage from the host.

Another feature of the invention is a method identifying a candidate therapeutic agent for treatment of cell proliferative disease induced by the presence of clonally expanded macrophages. The screening method involves transplantation of mammalian tumor tissue containing clonally expanded macrophages (such as a recombinant macrophage which contains a growth promoting cell proliferation gene operably attached to a functional transcriptional controlling region such as a promoter/enhancer region) into a mammal (such as a severe combined immunodeficiency (SCID) mouse). A cancer or other cell proliferative disease is allowed to develop in the mammal containing the implanted tissue. A pharmaceutically effective amount of a candidate therapeutic agent is administered to the mammal to determine if administration of the agent results in reduction in the size of the tumor, reduction in clonal macrophage viability, or reduction in clonal macrophage proliferation.

Another feature of the invention is a method of treatment of clonal macrophage-involved cell proliferative disease by first determining the presence of a clonally expanded macrophage in the diseased tissue. Second, the macrophage is substantially eliminated from the diseased tissue by administering to the mammal (preferably a human) harboring the diseased tissue, a therapeutic agent that is in a formulation for preferential uptake by a macrophage. The administering
is performed at a dose, at an interval and for a duration that is sufficient to substantially eliminate the macrophages (including the clonally expanded macrophages) from the mammal followed by discontinuation of the administering of the therapeutic agent such that the macrophage population of the mammal is regenerated.

Another feature of the invention is the treatment method described above wherein the therapeutic agent is DNA encoding antisense mRNA of a cell proliferation gene. The target cell proliferation gene is one positioned near (i.e., within 12 kb, preferably within 5 kb in distance from) a common site of HIV integration wherein the common site of HIV integration is shown by the diagnostic method of the invention to be clonally mutated. Introduction of the antisense-encoding DNA into the macrophage genome and expression of the antisense mRNA reduces expression of the cell proliferation gene.

Another feature of the invention is a therapeutic agent comprising DNA encoding a mutant form of a cell proliferation gene such that recombination into the endogenous cell proliferation gene of the macrophage genome results in the mutation being incorporated into the genome. The mutation of the cell proliferation gene is designed such that gene expression is substantially eliminated or that the expressed gene produces a substantially nonfunctional gene product.

Those of ordinary skill in the field of molecular biology will understand that any of a variety of conventional gene transfer methods may be used for introducing genes into cells. For example, physical methods for the introduction of DNA into cells include microinjection (see, e.g., Capecchi et al., Cell 22:479, 1980), electroporation (see, e.g., Reiss et al., Biochem. Biophys. Res. Commun. 137:244, 1986) and other standard methods. Chemical methods such as coprecipitation with calcium phosphate and incorporation of DNA into liposomes also have been used to introduce DNA into mammalian
cells, particularly macrophages as described herein. Finally, delivery of nucleic acids into mammalian cells can be executed through the use of viral vectors, in particular those derived from murine and avian retroviruses (see, e.g., Gluzman et al., *Viral Vectors*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988).

The invention can utilize a commercially available cytotoxic therapeutic agent such as trichosanthin (Lifson, J.D. et al., USPN 4,795,739; USPN 4,869,903; McGrath, M.S. et al., *PNAS* (1989) 86:2844-2848), alpha- or beta-momorcharin (Lifson, J.D., et al., *supra*), other single-chain ribosome inactivating protein or other cytotoxic agent well known in the art of HIV inhibition or cancer therapy. The cytotoxin may comprise multiple agents such that the combined actions of the agents results in cytotoxicity.

Trichosanthin is a plant protein obtained from the *Trichosanthes kirilowii* root tuber. It has homology to the amino acid sequence of Ricin A chain and may have ribosome-inhibitory properties similar to ricin and various single-chain ribosome-inhibitor proteins, such as momorcharin, pokeweed anti-viral protein (PAP), wheat germ inhibitor, and gelonin (Xuejun) (Lifson, J.D., et al., *supra*). Trichosanthin and momorcharin inhibit expression of HIV antigens in human blood cells including macrophages (Lifson, J.D., et al., *supra*).

Examples of other cytotoxic or proliferation-modulating agents include daunomycin, mitomycin C, daunorubicin, doxorubicin, 5-FU, cytosine arabinoside, colchicine, cytochalasin B, bleomycin, vincristine, vinblastine, methotrexate or the like. Also of interest are toxic agents which may be derived from microorganism or plant sources. Examples include the toxic subunits of naturally occurring toxins such as ricin, abrin, diphtheria toxin, saporin, and the like. Illustrative toxic subunits include the A chains of diphtheria toxin,

The cell proliferative disease treatment method of the invention features a liposome preparation containing within the liposome a macrophage-specific cytotoxin or a broad-spectrum cytotoxic agent. Such cytotoxin-containing liposome is prepared to be a size appropriate for the uptake of the cytotoxin-containing liposome preferentially by a phagocytic cell of the mononuclear phagocyte system (for example, a macrophage). A preferred cytotoxin for use in a macrophage 'suicide' technique is dichloromethylene-bisphosphonate (Cl,MBP or clodronate) as described by Van Rooijen and Sanders (Van Rooijen, N. and Sanders, A. (1994) J. Imm. Methods 174:83-93).

Targeting of the cytotoxin-containing liposome to a macrophage provides specificity of delivery and increased uptake. Targeting is accomplished by incorporation or attachment of a macrophage-specific antibody such as anti-CD14 to the liposome. Appropriate lipids and other agents and methods for the preparation of therapeutic liposomes are well known in the art (see e.g., Martin, P.J. and Papahadjopoulos, D., J. Biol. Chem. 257:286-288, (1982); Szoka, F. and Papahadjopoulos, D., Ann. Rev. Biophys. Bioeng. 9, 467-508, (1980); and Ostro, M.J. (ed)

Liposomes From Biophysics to Therapeutics, Marcel Dekker, Inc., New York, 1987).

The cancer treatment method of the invention additionally features an anti-macrophage cell surface antibody covalently attached to a cytotoxic agent such that the cytotoxic agent is preferentially taken up by a macrophage following attachment of the cell surface antibody-cytotoxin complex to a macrophage cell surface marker. Uptake of the complex is by a phagocytic process normal to the macrophage.

The proliferation-modulating agent and the targeting agent which provides binding to the extracellular matrix can be linked, usually by a bond which is cleavable, either intra- or extracellularly by reduction hydrolysis enzymatically, or by a bond which is acid labile. The type of linkage used depends upon a number of factors, but particularly the nature of the proliferation-modulating agent. For example, where the agent is one which must be internalized by a cell to have an effect, such as a toxin molecule or toxin A chain, it is preferable that the linkage to the targeting moiety can be cleaved. The targeting moiety can be linked to a drug either directly or indirectly by carrier molecules such as serum albumin (particularly human serum albumin), polyaminoacids, dextran, and the like, by methods well known to those skilled in the art. The use of a carrier molecule permits binding of multiple molecules of the proliferation-modulating agent to the linker molecule, preferably 10 to 30 molecules per molecule of carrier molecule for an antiproliferative compound, or 1 to 2 molecules per molecule of carrier molecule for a toxin molecule.

The type of linkage used can also be dictated by the cell type which is the ultimate goal of the proliferation modulating activity thus preferably the linkage is a Ph labile or acid labile link between the targeting moiety and the proliferation-modulating moiety in cases where
the cells have phagocytic properties, for example, fibroblasts and macrophages. Also of interest are peptide linkages which would be susceptible to hydrolysis by enzymes which may also be present in the extracellular matrix. Convenient linkages thus include disulfides, imides, hydrazones, amides and the like.

The cancer treatment method of the invention additionally features the complementary treatment of the non-macrophage cells of the tumor by conventional cancer therapy methods such that both the clonally expanded macrophage of the tumor and the non-macrophage cells of the tumor are each substantially ablated.

By "clonal macrophage" or "clonally expanded macrophage" is meant identical copies of a macrophage arising from a single progenitor macrophage.

By "clonality of DNA" is meant the degree to which DNA isolated from a cell population is the same as determined by the pattern of discernable DNA characteristics such as RFLP (restriction fragment length polymorphism), gene rearrangement by Southern analysis, IPCR, or other techniques known to those skilled in the art. Accordingly, a tissue sample is designated as having a monoclonal macrophage component if practice of the diagnostic method of the invention results in a distinct HIV-specific and/or macrophage-specific DNA band pattern of equal or greater intensity than a 5% control sample.

By "5% control sample" is meant a sample of known polyclonal DNA to which has been added a sample of known monoclonal DNA to constitute 5% of the total DNA.

By "promoter" is meant minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the native gene.
By "integrated into the genome" is meant exogenous DNA (such as an expression cassette or viral sequence) that is linearly incorporated within the genomic DNA chain of a cell (such as a macrophage) and is connected at each of its termini to the genomic DNA. Exogenous DNA encoding an expression cassette is integrated such that functional RNA or proteins are produced by the encoded sequences. An exogenous viral sequence is integrated such that expression of nearby endogenous

By "enhancer" is meant minimal sequence sufficient to enhance transcription substantially above wild type levels. Also included in the invention are those enhancer elements which are sufficient to enhance promoter-dependent gene expression controllable for cell-type specific or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the native gene.

By "pharmaceutically active amount" is meant an amount of an agent (such as a therapeutic agent) that when administered to a cell or a mammal results in a desired physiological effect (such as cytotoxicity, reduced viability, or substantially reduced proliferation).

By "substantial increase" or "substantially above" is meant an increase in expression, transcription or other process above the wild type level of that process where the increase is at least approximately 50% above wild type.

By "substantial decrease" or "substantial reduction" is meant a decrease or reduction in expression, transcription, or a measurable phenotypic characteristic that is approximately 80% of the wild type level, preferably reduced to approximately 50% of the wild type level, or more preferably reduced to approximately 10% or less of the wild type level.

By "substantially eliminated" or "substantial ablation" is meant a decrease in cell number such that
less than approximately 50% of the cells remain viable, preferably less than approximately 20% of the cells remain viable, or more preferentially less than 10% of the cells remain viable.

By "substantially reduced viability" is meant a decrease in the number of living cells in a population of cells relative to a control population such that less than approximately 50% of the cells remain viable, preferably less than approximately 20% of the cells remain viable, or more preferentially less than 10% of the cells remain viable.

By "pre-cancerous tissue" is meant mammalian tissue which is hyperplastic by histological examination and surgical-pathological evaluation well known to those skilled in the art of pathology.

By "cancerous tissue" is meant mammalian tissue which is no longer under the normal control of growth regulators. The cancerous nature of mammalian tissue is determined by surgical-pathological evaluation well known to those skilled in the art of pathology.

By "antisense" is meant nucleic acid wherein the noncoding strand of a target gene of interest is positioned for expression in a construct such that when expressed as mRNA, the single stranded antisense mRNA is complementary to and can hybridize to the mRNA of the target gene modulating its utilization. The sequence complementary to a sequence of the messenger RNA will usually be at least about 15 nucleotides, more usually at least about 20 nucleotides, preferably about 30 nucleotides or more, and more usually being fewer than 1000 nucleotides in length.

The particular site(s) to which the antisense sequence binds and the length of the antisense sequence will vary depending upon the degree of inhibition desired, the uniqueness of the sequence, the stability of the antisense sequence, or the like. Therefore, these
factors will be determined empirically based on the experience obtained with a particular antisense sequence.

By "operably attached" is meant a nucleic acid sequence to be expressed being fused at the 5′ end to a functional promoter element including transcriptional and translational (where applicable) initiation sites and being fused at the 3′ end to a functional transcriptional and translational (where applicable) termination sequence.

By "nucleic acid primer" is meant a single stranded nucleic acid sequence, preferably DNA, that hybridizes to a nucleic acid sequence of interest for priming of DNA synthesis by DNA polymerase. The nucleic acid primers of the invention are designed for use in the polymerase chain reaction method and inverse polymerase chain reaction method (Shiramizu, B. et al. (1994), supra) and as described herein.

By "labeled nucleic acid probe" is meant a single strand nucleic acid sequence to which is attached a label (such as a radiolabel; a biotinylation moiety; or other label known in the art and useful in Southern and Northern analyses). The nucleic acid sequence of the labeled probe used in the diagnostic method of the invention hybridizes to a genomic sequence near (i.e., within 5 kb, preferentially within 1 kb) a common HIV integration site. HIV integration at the site is associated with increased proliferation of the infected cell. An example of such a common integration site is the z exon of the fur gene where HIV integration is associated with macrophage proliferation (as described herein) or T-cell proliferation (Shiramizu, B. et al. (1994), supra).

By "cell proliferation" is meant increased cell growth in a test population above the rate of cell growth (e.g., cell division) of a control population such that cell growth is 20% above, preferably 50% above, or more preferably greater than 100% above a control population.
By "cell proliferative disease" is meant a disease state caused by excessive cell growth relative to the normal cell growth of the tissue. Such diseases include, but are not limited to, lymphoma, non-lymphoid cancer, AIDS dementia, atherosclerosis, nephropathy, and focal segmental glomerulo-sclerosis.

By "gene associated with cell proliferation" is meant a cell growth promoting gene (such as an oncogene) which when activated due to viral integration or other mutation results in increased cell proliferation. Cell proliferation genes include without limitation oncogenes such as c-fes/fps, ras, c-myc, c-sis and others well known in the art; and genes encoding cytokines such as IL-6 and IL-10. An activated oncogene means an oncogene which increases the probability of the development of neoplasms (particularly malignant tumors) in a mammal (particularly a human). A gene associated with cell proliferation also includes a cell growth suppressing gene such that decreased gene expression of a suppressor gene results in cell proliferation.

By "essentially non-functional mutated form of gene" is meant a gene or its gene product that is expressed or functions at 50%, preferably 20%, or more preferably less than 10% of wild type level.

By "preferential uptake by a macrophage" is meant a macrophage able to incorporate an agent to a greater extent (20% greater, preferably 50% greater, or more preferably more than 100% greater extent) than cells of other cell types in the cell culture or in the mammal.

By "kit" is meant a combination of physical elements such as specific primers, labeled probes and other elements useful to practice the invention. The diagnostic kit of the invention comprises elements useful for the diagnosis of clonal macrophages in a mammalian tissue sample.

By "macrophage" is meant a cell of the monocyte/macrophage lineage which is found in the spleen...
or has differentiated into a tissue macrophage. These cells include follicular dendritic cells (FDC), dendritic cells, Langerhans cells, as well as other tissue macrophages. The macrophage described herein is a non-tingible body macrophage not associated with scavenging cellular debris in the tissue. By "tissue" is meant any material isolated from a mammal includes body fluids such as blood, serum, cerebral spinal fluid, or any material which may contain macrophages for analysis by the method of the invention.

By "HIV" is meant a human immunodeficiency virus of strains HIV-1, HIV-2, or other variants.

The methods of the invention and the kit of the invention are preferably designed for the diagnosis and treatment of clonal HIV- and non-HIV-associated macrophage-induced cancer in a human.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Brief Description of the Drawings

The drawing will first be described.

Drawings

Fig. 1 is a schematic diagram of the IPCR method to detect integration sites. Primers CW1B (SEQ ID NO:1) and CW2H (SEQ ID NO:2) flank the LTR region in the opposite direction. The sequence of the primers and probes is shown. The location of the primers and probes is indicated as arrows above and below the genetic map of the fur gene integration site.

Fig. 2 shows a schematic diagram of HIV insertion into human c-sis.

Fig. 3 is a portion of the human c-sis proto-oncogene sequence into which HIV has inserted at intron 5. The sequenced DNA was IPCR products from macrophages obtained from cerebral spinal fluid of an
AIDS dementia patient. Insertion at nucleotide 343 is observed as reduced homology of the test gene (CSF2C2.DNA, SEQ ID NO:7) to the known c-sis sequence (HUMSIS5DEL, SEQ ID NO:6).

Description of the Preferred Embodiments

There now follows a description of the compositions and methods for determining the presence of clonal HIV in a tissue sample as well as descriptions of techniques useful in carrying out the invention. All publications mentioned in this specification are incorporated herein by reference for the purpose of disclosing and describing features of the invention for which the publications are cited. The examples below are provided for the purpose of illustrating the invention, and should not be construed as limiting.

Experimental Section

HIV and the Pathogenesis of Non-B-Cell Malignancies

As described above, some AIDS-associated non-B-cell lymphomas contain clonal forms of HIV. It is useful to determine the cell type that is clonally expanded in order to evaluate the necessary therapy. To determine the presence and clonal nature of HIV in pre-cancerous and cancerous tissue, two mixed immunophenotype lymphomas and one angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) specimens were analyzed. Southern blot analysis identifying a high level of HIV in three of these cases was performed as described in Materials and Methods. These lymphomas were found to have a single predominant form of HIV present within the tumor. All three of the tissue specimens had mixed immunophenotype morphology; two of them had no clonal B or T lymphocytes, whereas one had a clonal population of T-cells.
In order to map the integration site of the HIV sequences within these lymphomas, a process called inverse PCR (IPCR) was performed (Shiramizu, B. et al., (1994) supra). A schematic diagram of the IPCR technique is provided in Fig. 1. In this technique the integration sites of clonal forms of HIV were amplified by utilizing PCR primers complementary to sequences within the HIV LTR facing outward from each other, followed by restriction digestion, ligation, and DNA synthesis.

As shown in Fig. 1, when a clonal form of HIV is present within a tumor, a simple band pattern of one or two PCR bands will generally appear, each band representing an LTR with flanking cellular genomic sequence. The integration site from these mixed immunophenotypic specimens was mapped to a segment of the fur gene present on chromosome 15 just 5' to the c-fes/fps oncogene. This is the same integration site observed in a clonal HIV-associated T-cell lymphoma (Shiramizu, B. et al., (1994) supra) suggesting that integration of HIV upstream of the c-fes/fps oncogene leads to cellular expansion. IPCR was performed on tumor and non-tumor involved tissue from these three tumors as compared to the previously described T-cell lymphoma. Clonal IPCR products were amplified from these tumors whereas uninvolved lymph node and spleen from two of the cases showed no amplifiable sequences. Southern analysis using an internal LTR gene probe (SEQ ID NO:3) hybridized to both amplified IPCR products from each tumor, showing that each product had an LTR sequence. Two fur probes (SEQ ID NO:4 and SEQ ID NO:5) representing oligonucleotides at both the 5' and 3' ends of the 3' exon of fur were used in a Southern analysis of these IPCR products. One LTR-containing IPCR product from each case hybridized with this fur probe indicating that HIV had integrated in the 3' exon of the fur gene. Sequence analysis of one of these tumors confirmed the localization to this segment of the fur gene. The
integration site for one specimen mapped to base pair
position 301 and for another specimen mapped to base pair
1652 of the 2200 base pair 3' exon of fur.

To determine the sensitivity of the IPCR analysis,
DNA from the original T-cell lymphoma (Shiramizu, B., et
al., (1994), supra) was serially diluted into DNA
extracted from a hyperplastic lymph node from the same
patient. The IPCR technique has a sensitivity of between
2 and 5 percent in that clonal forms of integrated HIV
would only be amplifiable if they represented between 2
and 5 percent of the specimen (Shiramizu, B. et al.
(1994), supra). No forms of IPCR product have been
observed in hyperplastic nodes or splenic tissue from
HIV-infected individuals.

Clonal Forms of HIV are Found in Non-B-Cell Lymphomas

In order to test whether clonal HIV involvement
would be common in non-B-cell lymphomas, an IPCR analysis
was done on a spectrum of non-B-cell malignancies. The
IPCR method is detailed in Materials and Methods. This
spectrum included specimens from patients with mycosis
fungoides, cutaneous T-cell lymphoma, AILD, Hodgkin's
disease, and mixed immunophenotype lymphomas. Table I
lists the results of the IPCR analysis.
Table I

Summary of Cases and IPCR Results

<table>
<thead>
<tr>
<th>Case</th>
<th>Sample</th>
<th>Dx</th>
<th>IPCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>FUR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>DT</td>
<td>MF (cutaneous)</td>
<td>2 Bands</td>
</tr>
<tr>
<td>2.</td>
<td>GC-2</td>
<td>MF (cutaneous)</td>
<td>-</td>
</tr>
<tr>
<td>3.</td>
<td>EP</td>
<td>Lym (cutaneous)</td>
<td>-</td>
</tr>
<tr>
<td>4.</td>
<td>HK</td>
<td>Lym (cutaneous)</td>
<td>1 Band</td>
</tr>
<tr>
<td>10</td>
<td>JW</td>
<td>Lym (cutaneous)</td>
<td>1 Band</td>
</tr>
<tr>
<td>6.</td>
<td>RB</td>
<td>Lym (cutaneous)</td>
<td>2 Bands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N.D.¹</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>TPF</td>
<td>Lym (cutaneous)</td>
<td>1 Band</td>
</tr>
<tr>
<td>8.</td>
<td>WC</td>
<td>Lym (cutaneous)</td>
<td>1 Band</td>
</tr>
<tr>
<td>15</td>
<td>BR</td>
<td>T-cell (node)</td>
<td>2 Bands</td>
</tr>
<tr>
<td>10.</td>
<td>FR</td>
<td>Mixed immunophenotype</td>
<td>2 Bands</td>
</tr>
<tr>
<td>11.</td>
<td>AP</td>
<td>Mixed Immunophenotype</td>
<td>2 Bands</td>
</tr>
<tr>
<td>12.</td>
<td>BW</td>
<td>Mixed immunophenotype</td>
<td>2 Bands</td>
</tr>
<tr>
<td>20</td>
<td>GH</td>
<td>AILD</td>
<td>2 Bands</td>
</tr>
<tr>
<td>14.</td>
<td>CL</td>
<td>AILD</td>
<td>-</td>
</tr>
<tr>
<td>15.</td>
<td>TB</td>
<td>AILD</td>
<td>1 Band</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KS (brain)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(adrenal)</td>
<td>-</td>
</tr>
<tr>
<td>25</td>
<td>GS</td>
<td>Hodgkin’s</td>
<td>-</td>
</tr>
<tr>
<td>17.</td>
<td>JF</td>
<td>Hodgkin’s (kidney)</td>
<td>1 Band</td>
</tr>
<tr>
<td>18.</td>
<td>UM</td>
<td>Hodgkin’s</td>
<td>2 Bands</td>
</tr>
</tbody>
</table>

¹N.D.: not done.

The results are tabulated with the number of IPCR bands from each sample, where MF: mycosis fungoides; Lym: lymphoma; AILD: angioimmunoblastic lymphadenopathy; KS: Kaposi’s sarcoma. Additional tissue was available from three cases (9: uninvolved node; 15: uninvolved adrenal and KS of brain; 17: uninvolved kidney) which were used as internal negative controls. The results of
hybridization to the fur probe (column 5) are listed as positive or negative for samples which had IPCR bands.

The data in Table I indicate that fourteen of eighteen cases analyzed had clonal forms of HIV present within the tumor DNA. In each case where clonal forms of HIV were detected, one or two IPCR products were amplified. The size of amplified bands varied between specimens making it unlikely that the bands were a PCR artifact. In some cases immunophenotypic data confirmed the presence of HIV in cells present within the tumor. The Hodgkin's disease specimen UM was a syncytial variant Hodgkin's disease where all of the tumor cells were Reed-Sternberg cells which are related to cells of the macrophage lineage. These cells stained with anti-HIV-p24 antibody and a clonal form of HIV was identified by IPCR. All of the IPCR products also hybridized with an HIV LTR probe in Southern analysis. Six of 13 IPCR products hybridized with the previously described fur probes indicating that these six non-B-cell lymphomas had a clonal form of HIV integrated just 5' to the c-fes/fps oncogene.

Clonal HIV involvement was examined in four cases of Kaposi's Sarcoma. One in four of the specimens exhibited clonal HIV IPCR products and HIV p24 analysis localized HIV expression to macrophages adjacent to tumor cells.

c-fes/fps is Expressed in Tumor Tissue

Northern blot analysis was performed on RNA extracted from cases 9 and 10 of Table I above to determine whether c-fes/fps was expressed in tumor tissue having HIV integrated upstream of the c-fes/fps gene. The Northern blot showed the presence of a 3 kilobase pair (kb) c-fes/fps message from tumor mRNA, whereas the same message was not obtained form non-tumor mRNA. The 3 kb message is a size appropriate for the c-fes/fps mRNA which encodes a 92 kilodalton (Kd) tyrosine kinase (not shown). To determine whether the c-fes/fps mRNA would give rise
to Fes protein, a monoclonal anti-Fes antibody was obtained from ATCC (HB8595) and used in a series of immunohistochemical studies. Fes protein was detected frequently in tumor cells present in one of the mixed immunophenotype macrophage-rich lymphomas, whereas it was detected infrequently within a follicular hyperplastic HIV-infected lymph node.

A clonal form of HIV was also present within AILD, a disease process thought to represent a pre-lymphomatous state. Histologically the AILD GH specimen showed localization of the anti-p24 antibody to the cytoplasm of macrophages with some staining also present in a follicular dendritic pattern. Two color immunohistochemical analysis of tissue with anti-p24 (brown) and anti-fes (red) indicates the presence of dual colored cells (orange) expressing both p24 (from HIV) and c-fes/fps (activated by being positioned downstream of the HIV integration site). Macrophages were isolated from the GH AILD spleen by adherence, and the cells were dual stained with anti-Fes and anti-p24. Orange macrophages were observed showing that Fes and p24 co-localize in macrophages. Therefore, although no clonal form of T-cell or B-cell was present in the GH AILD, the finding of a clonal form of HIV and p24 expressed intracellularly with the AILD-associated macrophages suggests that the clonal form of HIV resides in a clonal macrophage-like cell. In the cases shown in Table I where frozen specimens were available, intense Fes staining was predominantly associated with macrophage-like cells as was p24 staining. One case however, showed intense Fes staining without p24 staining but had an abundance of clonal HIV integrated near (in the 3'z exon of fur) the c-fes/fps gene (Case 11). Therefore c-fes/fps expression can be influenced by HIV in the absence of HIV gene expression.
Cytokines are Involved in Macrophage-Associated Lymphomas

Cytokines are normally involved in lymphocytic proliferation. Interleukin-6 (IL-6) is a pleiotropic cytokine produced by various cell types that regulate immune responses, acute phase reactions and hematopoiesis (Akira, S. et al., Immunol Review (1992) 127:25-50). Many cell types, including monocyte/macrophages, fibroblasts, endothelia, B and T lymphocytes, chondrocytes, astrocytes and keratinocytes are capable of producing IL-6. IL-6 can exert growth-inducing, growth-inhibitory or differentiation inducing activities depending upon the nature of the target cells. In regard to lymphocytic stimulation IL-6 has been shown to be involved in 1) terminal differentiation of B-cells into antibody producing plasma cells; 2) induction of IL-2 and IL-2 receptors and differentiation of T-cells; and 3) IL-6 has been shown to cause growth of myeloma and hybridoma cells (Woodruff, C., et al., DNA and Cell Biology (1992) 11:587-592). IL-6 may cause transformation of IL-6 receptor expressing cells (Tohyama, N., et al., J Exp Med (1990) 171:389). IL-6 producing macrophages and endothelial cells were shown to be present in primary cultures of AIDS-associated large cell immunoblastic lymphomas (Emilie, D. et al., Blood (1992) 80:498-504), however no association with HIV integration or clonal macrophage expansion was described.

Inhibition of Cytokines In Vitro Blocks Lymphocytic Proliferation

Three patients with large-cell lymphoma malignant ascites were studied for in vitro effects of IL-6 and IL-10 on cell proliferation. The ascites fluid contained high concentrations of IL-6 and IL-10 and neutralizing antibodies to these cytokines blocked lymphoma cell proliferation. This observation is consistent with cytokines such as IL-6 and IL-10 inducing lymphomagenesis in vivo. The presence of a clonally expanded population
of macrophages associated with lymphoid tumors suggests that the macrophages, by secreting cytokines, are secondarily inducing surrounding untransformed cells to overgrow, thus causing tumorigenesis.

Identifying Cells Containing the Integrated HIV and Expressing Cytokine

Because many of the lymphomas that contain clonally integrated HIV represent mixed immunophenotype lymphomas that contain B-cells, T-cells, and prominent macrophages, it is important to determine which cell type contains the clonal form of HIV. As described in Table I above, multiple disease categories were described wherein HIV was found to be clonally integrated. These include mycosis fungoides, cutaneous T-cell lymphoma, systemic T-cell lymphoma, mixed immunophenotype/polyclonal lymphoma, AILD and Hodgkin’s disease. The same procedure is useful in analyzing various categories of lymphoma found to have integrated forms of HIV wherein cell subpopulations can be analyzed (by cell sorting or dual staining, for example) to identify the cell type containing the clonal HIV.

RFLP Analysis of Non-HIV Macrophages for Clonality

In the event that macrophage-rich cell proliferative disease tissue is found to lack HIV, the clonality of the cell population (e.g., the macrophage population) is determined as above by first sorting the cells into subpopulations according to cell surface marker reactivity. The macrophage or other cellular subpopulation is tested for clonality by RFLP analysis well known to those skilled in the art. RFLP analysis according to the invention involves probing the restriction digested and gel separated DNA with nucleic acid probes that hybridize to specific mammalian (preferably, human) genomic DNA regions.
The genomic regions of interest include, but are not limited to, regions which flank common viral (e.g., HIV) integration sites associated with cellular transformation such as sites near genes associated with the control of cell proliferation (e.g., an oncogene). The fur gene Z exon shown herein to be the site of HIV integration associated with clonal macrophage expansion is an example of a genetic region to which nucleic acid probes can be hybridized for determining clonality by RFLP analysis using the diagnostic method of the invention. It is well known in the art of molecular and cellular biology that genetic mutations or rearrangements can occur causing the abnormal expression of a particular gene such as an oncogene. Thus the integration of HIV or other virus is not required for abnormal expression of a gene adjacent to a frequently observed site of integration.

**Treatment of Lymphoma Containing HIV-Integrated Macrophages**

SCID mice are injected with human splenic tissue containing clonal HIV-integrated macrophages (e.g., tissue from Case 10). Control SCID mice are injected with normal (no HIV association, non-cancerous) splenic tissue. Growth of tumors in the control and test mice are monitored; the rate of growth of the HIV-associated tumor exceeds that of the control.

To illustrate the ability of a macrophage-targeted cytotoxic agent to inhibit the growth of macrophage-induced cancerous tissue, the following example is described. SCID mice harboring HIV-integrated macrophage-induced cancerous tissue (as described above) are divided into control and test groups. To test group 1 is administered a cytotoxic agent in a formulation that delivers the cytotoxic agent preferentially to the macrophages by the method of the invention (e.g., liposome encapsulated cytotoxin). To control group 1 is administered a formulation identical to that given to the
test group but without the cytotoxic agent. Tumor growth in test group 1 is compared to tumor growth in the control group 1.

Complementary treatment of the non-macrophage tumorous tissue further inhibits tumor growth. To test group 2 is administered the macrophage-targeted cytotoxic agent in a formulation as described above. To test group 2 is administered a second cytotoxic agent preferentially targeted to cell proliferative disease tissue (e.g., cancerous tissue). To control group 2 is administered only the second cytotoxic agent formulation targeted to cancerous tissue. The tumor growth in test group 2 is compared to test group 1 as well as the controls to determine the effectiveness of complementary treatment of the surrounding tissue while also treating the growth-inducing macrophages. Growth inhibition of both the clonally expanded macrophages and the surrounding tissue in complementary treatments further decreases the size of the tumor.

Pathogenic Model of Lymphomagenesis

The discovery of the invention is that HIV may play a direct role in the step-wise development of lymphoma in HIV disease. Clonal HIV-infected macrophages were present at a high frequency in polyclonal lymphoma and polyclonal AILD wherein no clonal B- or T-cell markers were observed. In a separate measurement of clonality (i.e. IPCR for mapping clonal forms of HIV) we have found HIV to be frequently present in a clonal form within these types of tumors. We have shown that in the cases examined, this clonal HIV was present within tumor-associated macrophages and thus, can be contributing to the polyclonal proliferation of lymphoma and angioproliferation of AILD through secretion of cytokines typically secreted by macrophages. The common integration site within 6 of 13 separate tumors indicated a role for c-fes/fps in the process of macrophage-induced
tumorigenesis. At least 5% of the cells within these tumors bears a clonal form of HIV, and the only cells found expressing HIV have been cells of the macrophage lineage except for the previously studied case where HIV was present in the malignant T-cells. Therefore we propose a model that a slow expansion of clonally infected macrophage-like cells represents an early stage in lymphomagenesis, and because of overstimulation of the lymphoid element with macrophage secreted cytokines (e.g., IL-6), leads to the development of polyclonal and subsequently monoclonal lymphomas.

Clonality isolated to one tissue type (e.g., macrophage) is indicative of early stage macrophage-induced tumorigenesis. Later stages are likely to contain clonal populations of other cell types as growth stimulation leads to outgrowth of some clones.

The development of clonal lymphoid lymphoma can also occur in hyperproliferative tissue through events such as chromosomal translocation where the chromosomal translocation within a clonal population of macrophages causes expression of an oncogene or overexpression of cytokines leading to tumorigenesis in the surrounding tissue.

The pathogenesis of Hodgkin's disease wherein the Reed-Sternberg cell is thought to contribute to gross tumor development through the expression of cytokines such as IL-6 parallels the clonal HIV-containing macrophage-induced lymphomas described above in that c-fes/fps is expressed uniformly in Reed-Sternberg cells in non-AIDS-associated Hodgkin's disease (Trumper, L.H. et al., Blood (1993) 81:3097-3115).
Experimental data: Materials and Methods

Detecting Clonally Integrated HIV-1 by IPCR

Using IPCR (inverse polymerase chain reaction), lymphomas from HIV-infected individuals were identified containing clonally integrated HIV-1.

DNA was extracted from fresh or frozen tissue by standard techniques as previously described (Maniatis, T., et al., Molecular Cloning: A Laboratory Manual (1982) Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). DNA from fixed paraffin-embedded tissue can be prepared for example by placing thin sections of the tissue in an Eppendorf tube and removing the paraffin with xylene. After rinsing with ethanol, the sample was digested with proteinase K (0.5 mg/ml) and 1% SDS at 50°C for 24 hours in TEN buffer (100 mM Tris-Cl, 40 mM EDTA, 10 mM NaCl, pH 8). The concentration of proteinase K and SDS are then adjusted to 1 mg/ml and 1%, respectively, and continue incubating for another 24 hours. Following phenol and chloroform:isoamyl alcohol extraction, the DNA is precipitated with sodium acetate and ethanol and dried.

IPCR was performed on DNA isolated from fresh, frozen and fixed tissue as described above or by equivalent techniques known to those skilled in the art. The procedure was performed as described by Shiramizu et al. (Shiramizu, B. et al., (1994), supra). DNA (0.1 μg) was digested with Sau3A (or other frequent cutter) and ligated in a 200 μl reaction: 1X ligase buffer (NEB, Beverly, MA), 40U T4 DNA ligase (NEB) for 36 hours at 15°C, a DNA concentration favoring self-ligation of the DNA fragments to form circles. The reaction was purified by ethanol precipitation and followed by IPCR (Fig. 1): 100 pmol primers (CW1B and CW2H, Fig. 1), 1 μl ligated product, 1X Taq1 DNA polymerase buffer, 20 nM dNTP’s, 2.5 U Taq1 DNA polymerase (Promega Biotech, Madison, WI) in a Cetus-Perkin Elmer thermocycler (Cetus-Chiron,
Emeryville, CA). Conditions: 94°C melting for 1.5 min, 50°C annealing for 1.5 min, 72°C extension for 3 min, for a total of 60 cycles. Amplified products were separated on an ethidium-stained gel (1-2% agarose/1-2% NuSieve gel, FMC BioProducts, Rockland, ME). To verify the amplified products, the DNA from the agarose gel was transferred to a nylon membrane and prepared for hybridization by standard techniques (Maniatis, T. et al., (1982) supra). The nucleic acid probes used for hybridization were LTRP, Fur1, and Fur2 (Fig. 1). The probes were labeled with digoxigenin and detected by chemiluminescence (Boehringer-Mannheim, Germany) or labeled by other standard techniques (e.g., radiolabel, biotinylation, fluorescence label).

To identify the cells containing the clonal HIV, the cell population is sorted as described above and the DNA isolated from each cell type is analyzed by IPCR. Alternatively, the DNA isolated from the mixed cell population is analyzed by IPCR followed by dual staining of tissue to localize an HIV product such as p24 in a particular cell type. In situ hybridization techniques are also standard in the art for the localization of specific sequences (such as HIV) in the event that the integrated HIV sequences are inactivated and do not produce identifiable proteins. Dual staining using anti-CD14 antibody and anti-p24 antibody would identify the dual stained cell as a macrophage containing HIV. Antibody staining is well known in the art; antibodies used for staining may be pre-labeled (covalently attached to a detectable marker) or labeled following attachment to the protein of interest (such as a biotin-IgG/streptavidin system well known in the art). The previously determined clonality of the HIV sequences indicate that the anti-p24 stained macrophage is a member of a clonally expanded population of macrophages associated with the cancerous tissue.
Flow Cytometry Cell Separation

The following procedure may be applied to any cell proliferative cell disease tissue such as kidney, atherosclerotic tissue, brain tissue of ADC patients, or lymphomas. As an example of a process for separating macrophages from non-macrophage disease tissue, the following procedure is described.

Single cell suspensions from newly diagnosed or cryopreserved lymphomas are prepared by pressing fresh lymphoma tissue through steel mesh screens. If the lymphoma contains a monoclonal HIV by IPCR, the single cell suspensions will be stained with monoclonal antibodies as previously described (Mercolino, T.J. et al., CD5 B cells in development and disease (1992) L. Herzenberg, K. Rawjesky and G. Haughton, eds., (New York Academy of Sciences) 409-421). Useful antibodies include: anti-CD14 which will identify macrophages; anti-CD4 which will identify CD4+ T-cells as well as macrophages; anti-CD8, anti-CD20 which identifies B-cells, anti-CD-30 (Ki-1); and anti-CD15 which identifies Reed-Sternberg cells. The cells are sorted using a FACS Vantage cell sorter or equivalent that has been equipped with a biohazard containment compartment capable of sorting live cell suspensions from HIV-infected specimens. Macrophages may be individually sorted from the other cells in a mixed population by initially tagging with a macrophage specific cell surface antibody such as labeled anti-CD14 followed by cell sorting and collecting anti-CD14 tagged cells separate from all other cells. The sorted cell specimens are subjected to IPCR as described above. Cytocentrifuge preparations from the sorted cells is stained with anti-HIV p24 antibodies by standard techniques to determine whether the cells containing clonally integrated HIV also express HIV structural determinants. Sorted cell populations are also useful for performing RT-PCR (reverse transcriptase
polymerase chain reaction) to determine the spectrum of cytokines expressed by each population of cells.

Alternatively, macrophages may be separated from other cell types in a mixed population by adherence to glass or plastic (such as glass or plastic beads or the sides of a glass or plastic container). Non-adhering cells are removed and retained for separate analysis as necessary.

**Double-Staining Immunocytochemistry**

A standard immunoperoxidase protocol well known in the art is used with slight modifications for double-antibody detection (Herndier, B.G. et al., AIDS (1994) 8:575-581. The p24 antibody (DAKO, Carpinteria, CA) is used for HIV localization. c-fes antibody was prepared from a hybridoma culture obtained from American Type Culture Collection (HB8595) (Gaithersburg, MD). If c-sis expression is to be tested, anti-c-sis antibody or an antibody to PDGF-B is obtained from commercially available sources.

The following technique is applicable to any tissue suspected of containing clonal macrophages. The double staining technique is applied to the detection of HIV and c-fes expression as an example.

Fixed-tissue slides were hydrated in graded ethanol with a final wash in distilled water. The slides were then blocked and buffered with 0.5% Casein in phosphate buffered saline (PBS) for 30 minutes. The p24 antibody was incubated on the slide for 1 hour at room temperature. The slide was then washed in Casein-PBS for 5 minutes. The slide was then incubated with biotin-conjugated anti-mouse IgG for 30 minutes at room temperature. The slide was washed in Casein-PBS for 5 minutes, followed by diaminobenzidine incubation for 7-10 minutes. After washing in distilled water, an incubation with 0.5% CuSO4 for 5 minutes was performed and washed with water for 2 minutes. The slide was then incubated for 10 minutes in 1N HCl, followed by a wash with water
and incubation in Casein-PBS for 15 minutes. The slide was then incubated with anti-\textit{fes} or anti-p24 antibody for 1 hour at room temperature, followed by a Casein-PBS wash. The slide was then incubated with biotin-conjugated IgG at room temperature (anti-mouse IgG made in horse; BioGenex, San Ramon, CA) for 30 minutes. After washing in Casein-PBS for 5 minutes, the slide was incubated with alkaline-phosphatase-conjugated streptavidin (BioGenex) at room temperature for 30 minutes. Following a wash in Casein-PBS for 5 minutes, the slide was then incubated with Vector Red Alkaline Phosphatase Substrate Kit I (Vector Lab) for 10-15 minutes, washed in water for 2 minutes and counterstained with Hematoxylin for 1 minute. The slide were washed in water for 1 minute followed by a wash of diluted ammonia in water, then followed by a wash of graded ethanol and xylene. This method was also useful for p24 staining. Means for detecting antibodies are well known in the art; the above procedure provides an example.

\textbf{Identifying c-fes/fps-Expressing Cells}

To identify cells expressing \textit{c-fes/fps} within tumors found to have HIV clonally integrated upstream of \textit{c-fes/fps}, two color immunofluorescence studies were performed as described above on fixed and permeablized cells. Antibodies described above for identifying cell type are used in a first immunostaining followed by a fixation and permeabilization with Ortho permafrix (Ortho Pharmaceuticals, Raritan, N.J.) (or equivalent) that will allow staining of intracellular Fes protein with an anti-\textit{fes} oncogene antibody (ATCC HB8595). These two-color studies are performed on tumor tissue as well as control lymph node tissue as there is a small amount of Fes expressed in normal macrophages. An activated form of a Fes-specific rabbit anti-sera can also be prepared by standard techniques as a useful stain since normal macrophages do not express the activated form of Fes.
The first stage antibodies are directly conjugated to FITC, whereas the second anti-fes antibodies have a phycoerythrin-labelled second stage antibody. The expression of other oncogenes such as PDGF-B is detected by the same procedure. An anti-PDGF-B antibody is obtainable from commercially available sources.

**Cytokine and Cell Proliferation Gene Expression**

Cytokine and cell proliferation gene expression is monitored by the following standard technique. Cellular RNA is extracted from sorted cell populations as previously described (Chomzynsky, P. and Sacchi N., *Anal Biochem* (1987) 162:145). Moloney leukemia virus reverse transcriptase is used to reverse transcribe cellular RNA into cDNA. RT-PCR utilizing cytokine primers designed to hybridize with the cDNA of known cytokines is performed on the cDNA as previously described (Trumper, L.H. *et al.*, (1993) *supra*; Brenner, C. *et al.*, *Biotechniques* (1989) 7:106). Useful primers include but are not limited to primers for Interleukins 1-13, c-fes/fps oncogene, c-sis (PDGF-B) oncogene, basic fibroblast growth factor, TNF-α (tumor necrosis factor-α), and GMCSF (granulocyte macrophage colony stimulating factor). Primers are easily designed and synthesized by one skilled in the art since the sequences of the relevant genes are known and synthetic techniques are routine.

**Macrophage Involvement in AIDS Dementia Complex (ADC)**

AIDS dementia complex is a serious complication of HIV disease which occurs predominantly in individuals with advanced immunosuppression. Clinically, patients with ADC have marked memory changes and are incapable of performing day-to-day functions. There is a profound inhibition of central nervous system function leading to slowing of intellectual process and ultimately to coma and death. Pathologically, the brain of an individual with AIDS dementia is characterized in part by 1) gliosis
(an over proliferation of astrocytes), 2) a loss of neurons, and 3) the development of multinucleated giant cells and microglial nodules. A prominent characteristic of brain tissue of an AIDS dementia patient is the presence of HIV-expressing macrophages (Watkins, B.A. et al. (1990) Science, 249:549-583). The increasing severity of dementia is correlated with increasing frequency of infected macrophages within the brain tissue. The increasing severity of dementia is correlated with increasing frequency of infected macrophages within the brain (Koenig, S. et al. (1986) Science, 233:1089-1093).

Growth factors are polypeptide hormones which stimulate a defined population of target cells. Examples of growth factors include platelet-derived growth factor (PDGF), insulin-like growth factors (IGF-1 and II), transforming growth factor beta (TGF-β), epidermal growth factor (EGF), and fibroblast growth factor (FGF). PDGF is a cationic, heat-soluble protein found in the granules of circulating platelets which is known to stimulate in vitro protein synthesis, collagen production by fibroblasts, and cell growth.

It is also known to act as an in vitro mitogen and chemotactic agent for fibroblasts, smooth muscle cells, glial cells, and astrocytes.

It is shown herein that HIV-infected macrophages in the brain of an AIDS dementia patient are clonal. Clonal macrophage proliferation in brain due to HIV infection is proposed to be associated with astrocyte proliferation resulting in gliosis. As a result, treatment of macrophage proliferation is a target of ADC treatment regimens.

Inverse PCR using the HIV LTR primers was performed on a series of DNA specimens isolated from the brains of several patients with AIDS dementia and from one cerebral spinal fluid specimen from a patient with AIDS dementia. HIV LTR primers were prepared by standard oligonucleotide
synthesis. The sequence of each primer and its length is chosen from the known sequence of HIV LTR (Shiramizu, B. et al., Cancer Res (1994) 54:2069-2072). The sequences of the IPCR primers (SEQ ID NO:1 and SEQ ID NO:2) were used in this example. Monoclonal inverse PCR products were identified in four specimens including the CSF specimen. The IPCR products from the CSF specimen were sequenced by standard techniques. The HIV integration site was mapped to the platelet derived growth factor B gene (PDGF-B) as shown in Fig. 3. A viral LTR sequence is shown inserted in the human c-sis gene (PDGF-B gene).

Two brain specimens were shown to have a RFLP-identified PDGF-B gene arrangement in brain by Southern analysis using the v-sis probe obtained from Oncor, Gaithersburg, MD. The results implicate PDGF-B involvement in macrophages from at least three specimens from brain and cerebral spinal fluid, obtained from individuals with HIV associated neurologic disease.

HIV integration within the PDGF-B gene (c-sis) is associated with persistent astrocyte proliferation and gliosis. This may occur by increased expression of macrophage PDGF-B driven by the HIV LTR enhancer element. AIDS dementia may thus be a primary process involving clonal macrophages that constitutively produce growth factors for astrocytes which then in turn cause secondary damage in the brain accounting for symptoms of ADC. Therefore, rather than HIV associated ADC occurring through a primary brain damage with resultant gliosis, clonal macrophage may drive gliosis causing secondary brain damage.

Diagnosis of clonal macrophage involvement in AIDS dementia

Cerebral spinal fluid is obtained from a patient presenting the symptoms of AIDS dementia. Macrophages are isolated from CSF, tested for clonality by IPCR, or
RFLP, or like method as described, supra. Clonality indicates that proliferation of macrophages is involved in the disease. Treatment is toward the substantial elimination of clonal macrophages from the brain. As a method of eliminating the clonal macrophages, treatments described above are useful in the treatment of AIDS dementia. However macrophage cytotoxic agents are chosen which cross the blood-brain barrier to target macrophages in the brain where they induce gliosis.

**Diagnosis of Macrophage Involvement in Proliferative Disease**

Circulating blood macrophages are analyzed for the presence of clonal HIV to predict patients who may be at risk to develop cell proliferative diseases. Macrophages are isolated from blood. DNA is analyzed by IPCR as described herein. Evidence of HIV clonality indicates that the patient has HIV insertion in macrophages and those macrophages are proliferating clonally. The patient is considered at risk of developing a cell proliferative disease in a tissue which is invaded by proliferating macrophages. Administration of cytotoxic agents to substantially reduce the number of proliferating macrophages is useful in preventing or reducing the likelihood of developing a cell proliferative disease.

**Macrophage involvement in Retrovirus-Induced Renal Disease**

retrovirus-induced renal disease when the following observations are considered.

Mesangial cells are specialized cells associated with the renal glomerulus and having properties of macrophages and contractile cells. Mesangial proliferation in the glomeruli is the most common renal lesion found in AIDS patients.

The lesion has been associated with a nephropathy (Rao, T.K.S. et al. (1984) supra) and is frequently found at autopsy (Pardo, V. et al. (1984) supra). Mesangial proliferation is conventionally considered to be a response to endothelial-basement membrane-epithelial injury. However, mesangial proliferation is proposed herein to be associated with macrophage proliferation in the area of the lesion. Proliferating macrophages have been hypothesized to be in communication with the mesangial cells via cytokines such as IL-1, IL-6, TGF-beta, and PDGF. These macrophages are proposed herein to be clonally proliferating as a result of viral integration at a site near or within a gene directing cell proliferation - proliferation of the virus-infected macrophage which, in turn, induces proliferation of the mesangial cell population into which the clonal macrophages have infiltrated.

The most common cause of renal failure in HIV disease is a nephrotic syndrome associated with focal segmental glomerulosclerosis (FSGS; Rao, T.K.S. et al. (1984) supra). The pathogenesis of FSGS is complex but includes diffuse mesangial proliferation (Couser, W.G. and Johnson, R.J. (1994) Am. J. Kidney Dis. 23:193-198). FSGS features a sclerosis of part of the glomerular structure which may be initiated by epithelial proliferation followed by matrix accumulation.

Secondary FSGS (not associated with HIV infection) involves glomerular injury due to increased capillary pressure caused by hypertension. The lesions of secondary FSGS are sclerotic and involve mesenchymal cell

The discovery disclosed herein regarding the association of HIV insertion in the PDGF-B gene of clonal macrophages which, in turn, are associated with cell proliferative disease provides a mechanism for HIV involvement in FSGS. Sequential pathogenesis may involve an initial proliferation (neoplasia) of mesangial cells which, as potential sources of PDGF, induce subsequent proliferation of mesenchymal cells such as endothelial cells and fibroblasts. Diagnosis of clonal macrophage involvement in renal disease provides early detection of disease as well as the development of treatment regimens that are directed to eradicating the source of the proliferation signal: the altered cytokine-producing macrophages and mesangial cells.

**Diagnosis of clonal macrophage-induced mesangial proliferation.**

Patients suspected of having renal disease such as nephrosis (protein in urine) or renal failure (increased BUN and creatinine levels) often undergo renal biopsy for pathologic diagnosis. The tissue is analyzed for HIV integration by IPCR technique. The cellular localization of clonal HIV integration is accomplished by disassociation of the tissue (by manual or enzymatic techniques) separating the tissue into cellular
components and isolating the macrophages. DNA from isolated macrophages can be subsequently analyzed by IPCR as above to confirm HIV clonality in macrophages. The finding of a consistent HIV integration site associated with renal disease indicates that proliferating macrophages are associated with the disease. The presence of clonal macrophages indicates abnormal macrophage proliferation and involvement in the cell proliferative disease of the patient.

If the patient is known or suspected to be infected with HIV, the DNA is further analyzed by IPCR using HIV LTR primers to amplify flanking genomic sequences. The flanking sequences are cloned into a vector for subsequent sequence analysis or Southern analysis in order to identify the region into which the HIV integrated.

**Clonal macrophage involvement in atherosclerosis**

It is disclosed herein that macrophage proliferation enhanced by retroviral insertional mutagenesis plays a role in the atherosclerotic process.

The formation of an atherosclerotic plaque is a complex interplay between vascular endothelium, intimal smooth muscle cells, intimal macrophages, and serum lipids. Atherosclerosis research has emphasized an understanding of serum lipid kinetics. Some researchers have concentrated on cellular proliferation and recruitment in the atherosclerotic plaque. Mutagenesis leading to atherosclerosis may include the viral insertion, integration of non-retroviruses, or any other form of mutagenesis which alters the expression of a cytokine. The result is clonal macrophage proliferation leading to induction of proliferation of other cell types and the observed proliferative disease.

Macrophages are components of atherosclerotic plaques. The number of macrophages in plaques is dependent on migration from circulating monocytes and on in situ

PDGF is a central cytokine in the pathogenesis of atherosclerosis. During atherosclerotic plaque formation platelets adhere to damaged subendothelium leading to an important event in the morbidity associated with atherosclerosis, the formation of thromboemboli. Adhered platelets can be an exogenous source of PDGF while mechanical factors such as shear stress (Sterpetti, A.V. et al. (1994) Eur. J. Vascular Surgery 8:138-142) and coronary spasm (Ogawa, H. et al. (1993) 4:437-442) can cause release of PDGF from intimal associated cells.

In human atherosclerotic lesions, PDGF-A and PDGF-B mRNA and protein are expressed in endothelial cells, smooth muscle cells, and macrophages (Barrett, T.B. and Benditt, E.P. (1988) P.N.A.S. USA 85:2810-2814). PDGF-B expression was localized to macrophages and PDGF-A expression was localized to smooth muscle actin expressing cells (Barrett, T.B. and Benditt, E.P. (1988) supra).

Mutagenesis, including retroviral insertional mutagenesis into the PDGF-B gene, for example, which affects proliferation of the mutagenized macrophages can be used as a diagnostic indicator of clonal macrophage involvement in atherosclerotic disease. Macrophages are recruited to the site of an atherosclerotic lesion and induced to proliferate by PDGF from such sources as platelets, in association with hypercholesterolemia, or
shear stress. The discovery disclosed herein of HIV insertion into or near the PDGF-B gene as an inducer of macrophage proliferation suggests that macrophages can be maintained in a clonal (neoplastic) state by mutagenesis (e.g., retroviral insertional mutagenesis); for example, by mutagenesis of a cellular growth factor gene such as PDGF-B.

Diagnosis of Cytokine Gene Mutagenesis and Macrophage Clonality in Atherosclerosis

Diagnosis of genetic alterations indicating clonal macrophage involvement in HIV or non-HIV-associated atherosclerosis are performed by the following steps. Macrophages are isolated from the blood of atherosclerosis patients by standard techniques such as flow cytometry or by adherence to a surface such as a glass or plastic surface. The DNA of the macrophages is subjected to Southern analysis to determine clonality and to RFLP analysis to determine possible insertional mutagenesis or genetic rearrangement in the area of the c-sis (PDGF-B) gene. Specific involvement of HIV by insertional mutagenesis is determined by IPCR using HIV LTR primers as previously described. The analysis can also be applied to any cytokine gene whose product is suspected of inducing macrophage proliferation.

Clonality of HIV insertion in macrophages was found by examining the atherosclerotic plaque of an AIDS patient who had atherosclerosis and had died of a heart attack. Tissue from the atherosclerotic plaque, the spleen, and the kidney of the patient was isolated and its DNA analyzed for HIV insertion and clonality by IPCR using IPCR primers CW1B (SEQ ID NO:1) and CW2H (SEQ ID NO:2). HIV clonality is observed as two DNA bands amplified by the primers which hybridize in the HIV LTRs (see Fig. 1). IPCR analysis showed two amplified DNA bands only for the atherosclerotic plaque tissue indicating that clonal HIV was present in the tissue. No bands were observed for
the spleen and kidney samples. Subsequent isolation of macrophages from the same tissue samples and analysis of the DNA by IPCR provided the same result - only macrophages from the atherosclerotic plaque contain clonal HIV.

There was no indication of cell proliferative disease in the spleen or kidney of the patient and the IPCR results indicate that no clonal HIV insertion was detectable in those tissues. Thus, a cell proliferative disease such as atherosclerosis is shown by IPCR analysis herein to be associated with HIV clonality.

Insertion of HIV into the PDGF-B gene was determined by RFLP analysis of DNA from macrophages of the atherosclerotic plaque tissue. Using the v-cis probe (Oncor, Gathersberg, MD) which hybridizes to sequences in the human PDGF-B gene, it was found that the PDGF-B gene was rearranged. Thus, the HIV insertion indicated by IPCR is shown to be associated with rearrangement of the PDGF-B gene. HIV clonality is the result of expansion of the macrophages having HIV inserted into the gene of the growth promoting factor, PDGF-B.

In addition, the atherosclerotic plaque tissue was stained with PCNA, a compound which stains only dividing cells by interacting with actively synthesizing DNA. Such histologic staining showed that macrophages were stained and were thus, actively dividing in the plaque tissue at the time the tissue was obtained. Proliferating macrophages having a rearranged PDGF-B gene is shown herein to be associated with the cell proliferative disease, atherosclerosis. PDGF-B gene rearrangement in this case is due to HIV insertion.

A showing of macrophage clonality in atherosclerotic patients indicates macrophages as inducers of endothelial proliferation and resultant plaque formation. Such diagnosis is useful in choosing macrophages as the target of atherosclerosis treatment.
Treatment of Cell Proliferative Disease Associated with Clonal Macrophages

Therapies directed against macrophages are described herein. Such therapies include but are not limited to delivery of cytotoxic agents to macrophages by liposomes. Liposomes are normally taken up by phagocytic cells such as macrophages. During phagocytosis of a cytotoxin-containing liposome, a cytotoxin such as dichloromethylene-bisphosphonate, is released intracellularly killing the phagocytic macrophage (Van Rooijen, N. and Sanders, A. (1994) supra).

A kit for the diagnosis of macrophage-induced cell proliferative disease is disclosed. The kit of the invention is useful for diagnosis of clonal macrophage involvement by testing DNA of macrophages isolated from a cell proliferative disease tissue. Clonality is determined to be DNA containing greater than 5% monoclonal DNA from macrophages. The kit of the invention features nucleic acid primers for amplifying DNA of an HIV-containing cell (e.g., a macrophage). The nucleic acid primers for amplification of HIV-containing DNA preferentially hybridize to regions of the 5' and/or 3' long terminal repeats (LTRs) such that DNA synthesis is primed in opposite directions for IPPCR analysis. Included in a kit is one or more labeled (e.g., radiolabeled; biotinylated; or other standard label) probes for RFLP analysis of genomic DNA for clonality where priming of HIV sequences is not desirable (e.g., in non-HIV-related cell proliferative diseases). Such a probe hybridizes to a genetic locus which is a common site of viral integration leading to cellular proliferation. Exemplary loci include, but are not limited to, c-fes/fps, c-sis, and other cell proliferation controlling genes.

Use
The invention is used for the early detection and diagnosis of clonally expanded macrophages in cell proliferative diseased tissue such as pre-cancerous or cancerous tissue, lymphoma, brain of AIDS dementia patients, atherosclerotic tissue, renal glomeruli. Clonality in macrophages indicates an early stage of cell proliferative disease induced by clonal macrophages since later stages often contain clonal populations of the surrounding tissue as well. Thus the diagnostic method and kit of the invention are useful in diagnosing the involvement of HIV in a given cell proliferative lesion or tumor; diagnosing the involvement of clonally expanded
macrophages inducing the growth of surrounding tissue; indicating the stage of tumorous growth so as to aid in the evaluation of a patient's disease; and providing information about the nature of the cell-proliferative diseased tissue such that alternative treatment may be followed if indicated.

The treatment method of the invention is useful in targeting the growth stimulating macrophages determined to be associated with the cell proliferative lesion by the diagnostic method of the invention. By inhibiting or ablating the cytokine-producing macrophages associated with the cell proliferative lesion, the growth of the surrounding tissue is substantially blocked. The treatment method of the invention is useful by further providing for the complementary treatment of macrophages as well as the growth-induced surrounding tissue leading to a complete treatment of the mixed immunophenotype lymphoma, AIDS dementia, atherosclerosis, nephropathy, or other cell proliferative disease tissue.

The invention is useful in diagnosing and treating several diseases associated with primary clonal expansion of a cell type (such as a macrophage or follicular dendritic cell) which induces a secondary cell to proliferate. Disease that can be diagnosed and treated by the invention are listed, without limitation, in Table II, column 1. The cell type (primary cell) which expands initially (through HIV insertion or genetic alteration resulting in expansion) and which induces other cells to proliferate is presented in column 2. The cells (secondary cells) which respond to the inducing signals and proliferate are presented in column 3. The invention is also useful in diagnosis and treating other diseases in which clonally expanded inducer cells promote proliferation of responder cells in early stages of a cell proliferative disease as shown, without limitation, in Table II.
### Table II

**Summary of Diseases That Can be Diagnosed and Treated by the Invention**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Primary Transformed Cell (&quot;Inducer&quot;)</th>
<th>Secondary Transformed Cell (&quot;Responder&quot;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucosal-associated lymphoid tumors</td>
<td>Follicular dendritic cell (lamina propria germinal cell)</td>
<td>B-cell</td>
</tr>
<tr>
<td>Follicular lymphoma</td>
<td>Follicular dendritic cell</td>
<td>B-cell</td>
</tr>
<tr>
<td>Autoimmune lymphomas</td>
<td>Defective retroviral infected macrophage (i.e., Sjögren's virus)</td>
<td>B or T-cell</td>
</tr>
<tr>
<td>Mycosis Fungoides</td>
<td>Langerhans cells</td>
<td>T-cell</td>
</tr>
<tr>
<td>Ki-1 positive anaplastic T-cell</td>
<td>Macrophage</td>
<td>T-cell</td>
</tr>
<tr>
<td>Kaposi's Sarcoma</td>
<td>Bowel macrophage</td>
<td>Endothelial cell</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>Bone marrow stroma</td>
<td>Plasma cell</td>
</tr>
<tr>
<td>AILD - B-cell</td>
<td>Defective follicular dendritic cell</td>
<td>B-cell</td>
</tr>
<tr>
<td>AILD - T-cell</td>
<td></td>
<td>T-cell</td>
</tr>
<tr>
<td>Polyclonal B-cell, Lymphoma</td>
<td>Defective follicular dendritic cell</td>
<td>Endothelial cell</td>
</tr>
<tr>
<td>Hodgkin's Disease</td>
<td>Reed-Sternberg cell</td>
<td>Lymphocytes and fibroblasts</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>Macrophage</td>
<td>Ductal cells and fibroblasts</td>
</tr>
<tr>
<td>AIDS Dementia</td>
<td>Macrophage</td>
<td>Astrocytes</td>
</tr>
<tr>
<td>Atherosclerosis</td>
<td>Macrophage</td>
<td>Smooth muscle cells</td>
</tr>
<tr>
<td>FSGS</td>
<td>Macrophage</td>
<td>Mesangial cells, Glomerular epithelium</td>
</tr>
</tbody>
</table>

Other embodiments are within the following claims.
SEQUENCE LISTING

(1) GENERAL INFORMATION:
   (i) APPLICANT: The Regents of the University of California
   (ii) TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF CELL PROLIFERATIVE DISEASE HAVING CLONAL MACROPHAGE INVOLVEMENT
   (iii) NUMBER OF SEQUENCES: 7
   (iv) CORRESPONDENCE ADDRESS:
       (A) ADDRESSEE: Robbins, Berliner & Carson
       (B) STREET: 201 W. Figueroa Street, 5th Floor
       (C) CITY: Los Angeles
       (D) STATE: California
       (E) COUNTRY: U.S.A.
       (F) ZIP: 90012-2628
   (v) COMPUTER READABLE FORM:
       (A) MEDIUM TYPE: Floppy disk
       (B) COMPUTER: IBM PC compatible
       (C) OPERATING SYSTEM: PC-DOS/MS-DOS
       (D) SOFTWARE: Patentin Release #1.0, Version #1.308
   (vi) CURRENT APPLICATION DATA:
       (A) APPLICATION NUMBER:
       (B) FILING DATE:
   (viii) ATTORNEY/AGENT INFORMATION:
       (A) NAME: Berliner, Robert
       (B) REGISTRATION NUMBER: 20,121
       (C) REFERENCE/DOCKET NUMBER: 5555-326
   (ix) TELECOMMUNICATION INFORMATION:
       (A) TELEPHONE: 213-977-1001
       (B) TELEX: 213-977-1003

(2) INFORMATION FOR SEQ ID NO:1:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 32 base pairs
       (B) TYPE: nucleic acid
       (C) STRANDEDNESS: single
       (D) TOPOLOGY: linear
   (ii) MOLECULE TYPE: cDNA

   (x) SEQUENCE DESCRIPTION: SEQ ID NO:1:
   GGATCCGGAT CCTCTNGATA GCCAGAAGCC TC
   32

(2) INFORMATION FOR SEQ ID NO:2:
   (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 32 base pairs
       (B) TYPE: nucleic acid
       (C) STRANDEDNESS: single
       (D) TOPOLOGY: linear
   (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
AAGCTTAAGC TTAGCTGAC TTGAGTCNT CA
32
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xii) SEQUENCE DESCRIPTION: SEQ ID NO:3:
GGTCTCTCTM GTTAGACCAG
20
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xiii) SEQUENCE DESCRIPTION: SEQ ID NO:4:
TGAGGATAG TTGAGCCCA AGTCTGAAG
30
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(xiv) SEQUENCE DESCRIPTION: SEQ ID NO:5:
CAGCACCCCT TCCATGGA GAAAGAGTG
30
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 350 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
AGATCGGCGC ACTGCACTCC AACCTGGGCA ACACGAGTGA CCTCCGCTCTT AAAAAAAT 60
AAATAAAAAG T GGGGAAGTCG GGCAAGAGGG CTTGAAAACTT CAGAGAAGCA 120
ATCGTGAGA GCCGGAGCTT TGGCACGAGT CGTAGATGAG TCAGAGAGTT GGTGAGGCC 180
ATCCCGACTT ACCAGTTTTCT AGATGGAAGA GGGCGAGAT TATGAGACGCA CACAGACCC 240
AGAAGCCCGG CTTCAGGTTG GGAAATGGAT TGTGCCCAAG AGCCGGAGT GCGCCACACC 300
ACGTGATCGG AGCGGGGCTGA GAGGTTGGGA GAAAACCTCA ATAGTGGTGC 350

(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 356 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(x) SEQUENCE DESCRIPTION: SEQ ID NO:7:
TACCTCGGCC ACTGCACTCC AACCTGGGCA ACACGAGTGA CCTCCGCTCTT AAAAAAAT 60
AAATAAAAAG T GGGGAAGTCG GGCAAGAGGG CTTGAAAACTT CAGAGAAGCA 120
ATCGTGAGA GCCGGAGCTT TGGCACGAGT CGTAGATGAG TCAGAGAGTT GGTGAGGCC 180
ATCCCGACTT ACCAGTTTTCT AGATGGAAGA GGGCGAGAT TATGAGACGCA CACAGACCC 240
AGAAGCCCGG CTTCAGGTTG GGAAATGGAT TGTGCCCAAG AGCCGGAGT GCGCCACACC 300
ACGTGATCGG AGCGGGGCTGA GAGGTTGGGA GAAAACCTCA ATAGTGGTGC 356
1. A method of screening for a candidate therapeutic agent that substantially reduces the viability of a macrophage, said method comprising:
   administering to a proliferating macrophage a pharmaceutically effective amount of a candidate therapeutic agent in a formulation for preferential uptake by a macrophage, wherein said uptake results in substantially reduced viability of said macrophage.

2. A method of diagnosing the presence of clonally expanded macrophages in a tissue of a mammal, said method comprising:
   determining the presence of clonal DNA in DNA of cells from said tissue, wherein said determining uses at least one single stranded nucleic acid fragment that hybridizes to DNA isolated from a macrophage in said tissue sample.

3. The method of claim 2, wherein before said determining, said method comprises separating a macrophage from other cells of said tissue.

4. The method of claim 2 wherein:
   a) said isolated DNA contains a genomically integrated copy of a virus; and
   b) said determining is performed by the method of inverse polymerase chain reaction (IPCR);
   c) said single stranded nucleic acid fragment comprises a pair of nucleic acid primers that hybridize to sequences of said virus.

5. The method of claim 4 wherein:
   a) said virus is a human immunodeficiency virus; and
   b) said pair of nucleic acid primers hybridize to long terminal repeat (LTR) sequences of said human immunodeficiency virus.
6. The method of claim 2 wherein:
   a) said determining is performed by RFLP analysis; and
   b) said single stranded nucleic acid fragment hybridizes to a genomic sequence associated with a genetic alteration resulting in substantially increased cell proliferation.

7. The method of claim 6 wherein said genomic sequence is a site of human immunodeficiency virus integration.

8. The method of claim 6 wherein said genetic alteration results in substantially increased expression of a gene promoting cell proliferation.

9. The method of claim 8 wherein said gene is an oncogene.

10. The method of claim 9 wherein said oncogene is selected from the group comprising c-fes/fps, c-myc, ras, and PDGF-B.

11. The method of claim 6 wherein said sequence is the z exon of the fur gene.

12. The method of claim 6 wherein said sequence is the c-sis gene.

13. A composition for use in a method of treating cell proliferative disease in a mammal, said composition comprising:
   a pharmaceutically effective amount of a therapeutic agent that is in a formulation for preferential uptake by macrophages;
wherein a portion of said macrophages are in the tissue of a mammal in which tissue the presence of a clonally expanded macrophage has been determined;
wherein said uptake results in substantially eliminating said clonally expanded macrophages from said mammal; and
wherein the macrophage population of said mammal is regenerated after the administration of said composition is discontinued.

14. The composition of claim 13 wherein said therapeutic agent is a cytotoxin.

15. The composition of claim 14, wherein said therapeutic agent is selected from the group of cytotoxins consisting of trichosanthin, momorcharin, daunomycin, mitomycin C, daunorubicin, doxorubicin, 5-FU, cytosine arabinoside, colchicine, cytochalasin B, bleomycin, vincristine, vinblastine, methotrexate, ricin, abrin, diphtheria toxin, saporin, the A chains of diphtheria toxin, exotoxin-A, ricin A-chain, abrin A-chain, modeccin A-chain, saporin.

16. The composition of claim 13, wherein said formulation is a liposome formulation.

17. The composition of claim 13, wherein said formulation is an anti-macrophage cell surface protein antibody covalently attached to a cytotoxin.

18. The composition of claim 13, wherein said formulation is an antibody to a cell surface marker of an HIV-infected macrophage wherein said antibody is covalently attached to a cytotoxin.
19. The composition of claim 13, wherein said composition further comprises:
   a pharmaceutically effective amount of a second therapeutic agent preferentially cytotoxic to cancer cells that is sufficient to substantially ablate said cancer cells.

20. A composition for use in a method of treating a cell proliferative disease in a mammal, said composition comprising:
   a pharmaceutically effective amount of a therapeutic agent that is in a formulation for preferential uptake by macrophages;
   wherein a portion of said macrophages are in the tissue of a mammal in which tissue the presence of a clonally expanded macrophage has been determined; and
   wherein said uptake results in substantial reduction in expression of a growth promoting cell proliferation gene in said clonally expanded macrophage resulting in substantial reduction in growth of said clonally expanded macrophage.

21. The composition of claim 20 wherein:
   a) said therapeutic agent is a DNA encoding an antisense sequence of a growth promoting cell proliferation gene; and
   b) said antisense sequence is operably attached to DNA sequences for integration into said genome of said macrophage and is operably attached to a promoter for expression in said macrophage.

22. The composition of claims 13 and 20 wherein said cell proliferative disease is from the group consisting of lymphoma, non-lymphoid cancer, AIDS dementia, atherosclerosis, nephropathy, and focal segmental glomerulosclerosis.
23. The composition of claims 2, 13, or 20, wherein said mammal is a human.

24. A kit for diagnosing the presence of a clonally expanded macrophage in a tissue of a mammal by the method claim 2, said kit comprising:
   a) a pair of nucleic acid primers for amplification of a DNA sequence isolated from said tissue wherein said amplification is indicative of clonally expanded DNA;
   b) a nucleic acid probe for restriction fragment length polymorphism (RFLP) analysis of DNA isolated from said tissue wherein genetic alteration of said DNA is associated with cell proliferation; and
   c) a detectable antibody to a macrophage-specific cell surface protein for identifying a macrophage.
**FIG. 1**

![Diagram of molecular structure](image)

**Two Amplified Fragments**

<table>
<thead>
<tr>
<th>PRIMERS/PROBES</th>
<th>SEQUENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>CW1B</td>
<td>5'-GGATCCGGATCCCCCTNGNTAGCCAGAGGCTC-3' (SEQ ID NO:1)</td>
</tr>
<tr>
<td>CW2H</td>
<td>5'-AAGCTTAAGCTAGCTTGGCCTTGGAGTGTCCCA-3' (SEQ ID NO:2)</td>
</tr>
<tr>
<td>LTRP</td>
<td>5'-GGTCTCTCCTGTAGACCCAG-3' (SEQ ID NO:3)</td>
</tr>
<tr>
<td>FUR1</td>
<td>5'-TGAGGAATAGTTGAGCCCCAACAGTCTGAAG-3' (SEQ ID NO:4)</td>
</tr>
<tr>
<td>FUR2</td>
<td>5'-CAGCACCCCCCTTCCATGTTGGAAAAAGGAGTG-3' (SEQ ID NO:5)</td>
</tr>
</tbody>
</table>

N:G,A,T,C

**HUMAN c-sis GENE (EXONS 1-7): ENCODES PDGF**

![Diagram of gene structure](image)

**FIG. 2**

CASE 1, INTEGRATED VIRUS
(5'-LTR...TCGCGCCACTGCACTC...3'-LTR)

SUBSTITUTE SHEET (RULE 26)
<table>
<thead>
<tr>
<th></th>
<th>CSF2C2.DNA</th>
<th>HUMSIS5DEL</th>
</tr>
</thead>
</table>
|            | TACTCGCGCCACTGCACCTC
gcaacgagagtga
ccctngctcttttttaaaacaat | AGATCGCGCCACTGCACCTC
ccacgcagagctgaccctccgtcttttttaaaacaat |
|            | X:                  | 109 119 129 139 149 159 |
|            | 780 790 800 810 820 830 |
|            |                     | 169 179 189 199 209 219 |
|            | CSF2C2.DNA          | HUMSIS5DEL         |
|            | AAATACAGATGCGAANTCGAGGCAAGCGGTGTTAAGTGAACCCTGAGACTGCTGAAATGTCACCA |
|            |                     | AAATACAGATGCGAANTCGAGGCAAGCGGTGTTAAGTGAACCCTGAGACTGCTGAAATGTCACCA |
|            |                     | 840 850 860 870 880 890 |
|            |                     | 229 239 249 259 269 279 |
|            | CSF2C2.DNA          | HUMSIS5DEL         |
|            | TACGTGGAGAGCCCAAGATTTNAGCAGTGGCTGGTCACATCAGCGGTGACCTGTTGAGGCC |
|            |                     | TACGTGGAGAGCCCAAGATTTNAGCAGTGGCTGGTCACATCAGCGGTGACCTGTTGAGGCC |
|            |                     | 900 910 920 930 940 950 |
|            |                     | 289 299 309 319 329 339 |
|            | CSF2C2.DNA          | HUMSIS5DEL         |
|            | ATCCCCACTCTACCATTTCAGAGGCAAGCTGGTCAGTGGCAAGGCAACAACTCTGACC | ATCCCCACTCTACCATTTCAGAGGCAAGCTGGTCAGTGGCAAGGCAACAACTCTGACC |
|            |                     | 960 970 980 990 1000 1010 |
|            |                     | 349 359 369 379 389 399 |
|            | CSF2C2.DNA          | HUMSIS5DEL         |
|            | CGAAAGTGTTGGAAAGAGTG
ccacgcagtatgccctgcataagcagcgtgntttg | CGAAAGGCCAGCTTCATG-GTGG-GAG---TATGATTCTGGCCAGAGGCCAGTGCCCTCC |
|            |                     | 409 419 429 439 449 |
|            | CSF2C2.DNA          | HUMSIS5DEL         |
|            | CCTGTACTGGCTCTCTCTG
nttagacactctgacgcctggagtcacctgactaact | ACACCAGTGATCGGACGGGCTGA-GAGGTTGGGAGGAAACCTCAATAGTAGGTC |
|            |                     | 1070 1080 1090 1100 1110 1120 |
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 49/00; C12Q 1/68; C12P 21/06, 19/34
US CL : 424/9.2; 435/6, 69.1, 91.2

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)


Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>BLOOD, Volume 80, No. 2, issued 15 July 1992, Emile et al., &quot;Interlukin-6 Production in High-Grade B Lymphomas: Correlation with the Presence of Malignant Immunoblasts in Acquired Immunodeficiency Syndrome and in Human Immunodeficiency Virus-Seronegative Patients&quot;, pages 498-504, see entire document.</td>
<td>1-24</td>
</tr>
</tbody>
</table>

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

* Special categories of cited documents:
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier document published on or after the international filing date
  *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search: 10 OCTOBER 1995
Date of mailing of the international search report: 19 OCT 1995

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
Bradley L. Sisson
Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US, A, 4,795,739 (LIFSON ET AL.) 03 January 1989, see entire document.</td>
<td>1-24</td>
</tr>
<tr>
<td>Y</td>
<td>US, A, 4,869,903 (LIFSON ET AL.) 26 September 1989, see entire document.</td>
<td>1-24</td>
</tr>
<tr>
<td>A</td>
<td>US, A, 5,177,192 (PAK ET AL.) 05 January 1993, see entire document.</td>
<td>13-24</td>
</tr>
<tr>
<td>Y</td>
<td>US, A, 4,681,840 (STEPHENSON ET AL.) 21 July 1987, see entire document.</td>
<td>1-12 and 24</td>
</tr>
<tr>
<td>Y</td>
<td>US, A, 4,699,877 (CLINE ET AL.) 13 October 1987, see entire document.</td>
<td>2-12 and 24</td>
</tr>
<tr>
<td>Y</td>
<td>US, A, 5,225,326 (BRESSER ET AL.) 06 July 1993, see entire document.</td>
<td>2, 3</td>
</tr>
<tr>
<td>Y</td>
<td>US, A, 4,800,159 (MULLIS ET AL.) 24 January 1989, see entire document.</td>
<td>4-12, 24</td>
</tr>
</tbody>
</table>
B. FIELDS SEARCHED
Minimum documentation searched
Classification System: U.S.
424/9.1, 9.2, 147.1, 148.1, 152.1, 153.1, 172.1, 173.1, 450; 435/S, 6, 7.1, 69.1, 91.2, 236, 270, 974; 935/33, 34, 59, 76, 77, 78

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS
Search Terms: pharmaceutical, therapeutic screen?, HIV, AIDS, oncogene, gene therapy, cytotoxin?, anti-macrophage, antibody, immunoglobulin